Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | CDK1 | P06493 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328372 | 0.92 | CDK1 (0.67) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL23328875 | 0.86 | KMT2A (0.63) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL23328446 | 0.85 | MEN1 (0.63) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL23328399 | 0.83 | CDK1 (0.61) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL25840806 | 0.82 | RECQL (0.52) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL31276967 | 0.81 | CDK1 (0.82) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL23328371 | 0.81 | CDK1 (0.59) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL23328393 | 0.80 | SMN1; SMN2 (0.68) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL27922870 | 0.80 | MEN1 (0.68) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL25841058 | 0.79 | LMNA (0.72) | MEN1KMT2ASMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | Kent Innovation & Enterprise (GB) | 2023-07-18 | — | — | US | disclosed |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | ARF1, ARL1, TLR1 | MEN1 1300/4885KMT2A 2533/4885SMN1; SMN2 3087/4885 |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | ARF1, ARL1, TLR1 | MEN1 1300/4885KMT2A 2533/4885SMN1; SMN2 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.